



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 438 147 A2**

12

EUROPEAN PATENT APPLICATION

21 Application number: **91100509.8**

51 Int. Cl.⁵: **A61K 37/30, A61K 9/20**

22 Date of filing: **17.01.91**

30 Priority: **19.01.90 IT 1911290**

43 Date of publication of application:
24.07.91 Bulletin 91/30

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

71 Applicant: **SCLAVO S.p.A.**
Via Fiorentina 1
I-53100 Siena(IT)

72 Inventor: **Lattanzi, Filippo**
Via Sansedoni, 9
I-53100 Siena(IT)
Inventor: **Cecchetti, Maurizio**
Via Diaz, 13/C
I-25100 Brescia(IT)
Inventor: **Vanni, Riccardo**
Via Montesanto, 3
I-53100 Siena(IT)

74 Representative: **Gervasi, Gemma et al**
NOTARBARTOLO & GERVASI Srl Viale
Bianca Maria 33
I-20122 Milan(IT)

54 **Pharmaceutical compositions and dosage forms for the oral administration of calcitonin.**

57 New pharmaceutical compositions containing a calcitonin as active principle and suitable for oral administration in the form of perbuccal and sublingual tablets are described, in which the active principle is homogenized with a mixture of solid excipients, said excipients consisting of a diluent, a lubricant, a disintegrating agent in the case of sublingual tablets, and a binder in the case of perbuccal tablets.

Said compositions enable the same pattern of hematic levels to be obtained for the same unit dose as obtainable by conventional intramuscular administration.

EP 0 438 147 A2

PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR THE ORAL ADMINISTRATION OF CALCITONIN

This invention relates to pharmaceutical compositions containing a calcitonin as active principle, homogenized with a mixture of solid excipients suitable for oral administration in the form of tablets.

In particular, the present invention relates to sublingual and peribuccal tablets suitable for the oral administration of a calcitonin, obtained using said pharmaceutical compositions.

5 The calcitonins constitute a known class of pharmacologically active long-chain polypeptides the use of which has been well described in the literature. Various calcitonins, including for example salmon and eel calcitonin, are currently used for treating for example Paget's disease, Sudek's disease and osteoporosis.

However, the preparation of an appropriate and effective means of calcitonin administration has caused numerous difficulties. In this respect, as in the case of polypeptides in general, when administered orally
10 they are easily degraded by the proteolytic enzymes present in the gastrointestinal tract, which rapidly hydrolyze them to oligopeptides free of pharmacological activity, they then being metabolized by the liver.

For these reasons, the pharmaceutical forms in which calcitonins are commonly sold are suitable only for intramuscular or intravenous administration of the active principle.

Such a method of administration is however inconvenient, especially in the case of lengthy treatment.

15 In this respect it has been found that after prolonged parenteral calcitonin treatment, side effects such as diarrhea, sudden perspiring, hot flushes and a sense of vexation arise.

Other methods of calcitonin administration have been proposed in the art, such as nasal and rectal. These administration methods involve however considerable problems.

For example, nasal clinical treatment using a nasal spray results in very low absorption of the active principle, even if high doses are used. Specifically, using doses four times greater than those used for
20 parenteral administration, an absorption of 30% is obtained.

In addition, it has been observed that the absorption is further reduced in elderly people, who represent those most afflicted by the aforesaid pathologies.

The possibility of administering these active principles orally has been the object of considerable study
25 in recent years.

However, the results obtained have shown that even in the case of adequately protected calcitonins a rapid degradation of the active principle occurs, with a corresponding low level of absorption.

The object of the present invention is consequently to find other calcitonin administration means which overcome the drawbacks of the known art.

30 It has now been found that an effective clinical treatment can be achieved by administering calcitonins orally in the form of peribuccal and sublingual tablets.

More specifically, the applicant has found, in accordance with the teachings of the present invention, that hematic calcitonin levels equivalent to those obtained by intramuscular administration in the usual doses can be obtained by oral administration of a calcitonin in the form of peribuccal or sublingual tablets in
35 doses which fall within the limits of tolerability and practicality.

Oral administration is a simple and painless method which can be easily used by the patient himself, employing peribuccal or sublingual tablets.

Although such administration is preferable to parenteral administration, such as by injection as commonly practised up to the present time, the preparation of a composition appropriate to this type of
40 administration presents certain difficulties.

One of these, which is particularly delicate in relation to oral administration of complex active principles such as the calcitonins, is to provide a totally compatible and effective means.

In this respect, a pharmaceutical composition for oral application in the form of sublingual and peribuccal tablets must be well tolerated, particularly at the site of its application, must not irritate the
45 mucosa, and must not result in a too rapid disintegration of the tablet in the case of peribuccal tablets, which disintegration furthermore must be incomplete or absent in the case of sublingual tablets.

In addition the results obtained must be uniform, with corresponding uniformity of bioavailability of the active principle.

The concept of bioavailability of a pharmaceutical product has become of great interest in recent years
50 as it is directly related to therapeutic efficiency. Bioavailability can be defined as the quantity of medicament absorbed into the blood from an administered pharmaceutical product. The bioavailability of a pharmacologically active compound depends on numerous factors, such as the excipients used for preparing the pharmaceutical compositions, the technology used for preparing the dosage forms and the physico-chemical properties of the active principle. Thus two products of the same type (tablets) containing

the same quantity of the same active ingredient can show different degrees of bioavailability, ie they are chemically equivalent but not necessarily bioequivalent. For two chemically identical products to be bioequivalent they must attain the same plasmatic concentration within the same time.

The present invention therefore provides pharmaceutical compositions containing a calcitonin as active principle and suitable for oral administration in the form of perbuccal and sublingual tablets in which said calcitonin is homogenized with a mixture of solid excipients, said excipients consisting of a diluent, a lubricant, a disintegrating agent in the case of sublingual tablets, and a binder in the case of perbuccal tablets.

The invention also provides unit dosage forms for the oral administration of a calcitonin in the form of perbuccal and sublingual tablets, prepared using said compositions.

Further aspects of the present invention will be apparent from the following description and examples.

Specifically, the pharmaceutical compositions of the present invention consist of a homogenate of the active principle, possibly mixed with a suitable stabilizer, with a mixture of solid ingredients, said mixture consisting of:

- 1) a completely soluble diluent consisting of mannitol and one or more sugars;
- 2) a disintegrating agent in the case of sublingual tablets, or a binder to slow down dissolution in the case of perbuccal tablets; and
- 3) a lubricant.

The active principle for use in the formulations of the present invention can be chosen from calcitonins of natural or synthetic origin such as salmon calcitonin (SCT), eel calcitonin (ECT) or pig calcitonin, or synthetic analogues such as (Asu^{1,7})ECT commonly known as carbocalcitonin.

The quantity of active ingredient to be used in the composition depends on the type of calcitonin used, the disease to be treated, the desired frequency of administration and the desired effect. Generally, active principle quantities of between 20 and 800 I.U. and preferably between 50 and 500 I.U. per tablet (100-150 g) are used.

Diluents suitable for the purposes of the present invention can be chosen from mannitol, lactose, saccharose or a mixture of lactose and saccharose in a quantity of between 20 and 70% and preferably between 30 and 55% by weight with respect to the total weight of the tablet.

Disintegrating agents suitable for the purposes of the present invention are chosen from starch, sodiumcarboxymethyl starch, carboxymethylcellulose, microcrystalline cellulose, crospovidone, amberlite and alginic acid in a quantity of between 1 and 15%, and preferably 5-10% in the case of microcrystalline cellulose and 1-3% in the case of the other disintegrating agents, by weight with respect to the total weight of the tablet.

Binders able to delay solubilization of the perbuccal tablet are chosen generally from gum arabic and cellulose derivatives such as hydroxypropylcellulose and hydroxypropylmethylcellulose in a quantity of between 1 and 25% and preferably between 5 and 10% by weight with respect to the total weight of the tablet.

Lubricants are chosen from magnesium stearate, aluminium stearate, stearic acid, high molecular weight PEG or talc, in a concentration of between 0.3 and 5% and preferably between 0.5 and 2%.

According to the present invention the pharmaceutical compositions for the preparation of sublingual and perbuccal tablets can also contain colouring and flavouring agents.

The compositions according to the present invention are well tolerated and do not induce undesirable side effects.

In addition the results obtained indicate the appearance of calcitonin in the blood within 4-5 minutes of administration.

In particular, the compositions described in Examples 1 and 2 for the preparation of sublingual tablets are distinguished by a bioavailability with in the first case peaks of lesser but constant intensity (150-160 pg/ml), and in the second case a peak of greater intensity (200-210 pg/ml) and a more rapid decline, but which remains at a good level (Figures 1 and 2).

One characteristic of the compositions of the present invention and in particular of this method of administration is the surprising uniformity of the results and hence of the bioavailability of the active principle.

The absorption of the active principle, which is practically immediate and less sensitive to variables, is between 70% and 90%.

These dosage forms offer advantages such as stability, accuracy and precision together with good bioavailability of the active principle.

When the best formulation has been established, the tablets can be prepared by directly compressing the pulverized or granulated mixture of the active principle and excipients using currently available

equipment for this purpose.

The following examples illustrate in greater detail some formulations and some unit dosage forms representative of the present invention, and the experimental results obtained on administering some of these.

5

EXAMPLE 1

Sublingual tablets

10 Sublingual tablets weighing approximately 100 mg were prepared having the following composition:

	ECT	50.00 U.I.
15	Lactose	42.00 mg
	Saccharose	40.00 mg
20	Microcrystalline cellulose	6.00 mg
	Amberlite IRP88	2.00 mg
	Magnesium stearate	0.90 mg

25

These tablets were administered to a group of 18 healthy volunteers. When placed under the tongue the tablets, which were odourless and of pleasant taste, dissolved within one minute at the most.

Blood samples were taken at time 0 and at 5, 10, 60, 90 and 120 minutes after administration.

The calcitonin concentration in the serum was determined by radio-immunological assay.

30

The mean results for the 18 volunteers are shown in Figure 1.

These results show the appearance of eel calcitonin in the blood within 4-5 minutes from administration. Side effects did not appear.

EXAMPLE 2

35

Sublingual tablets weighing approximately 100 mg were prepared having the following composition:

	ECT	50.00 U.I.
40	Ludipress	50.00 mg
	Saccharose	40.00 mg
45	Microcrystalline cellulose	9.00 mg
	Magnesium stearate	1.00 mg

where ludipress is lactose plus polyvinylpyrrolidone (PVP).

50

These tablets were administered to a group of 18 volunteers, of whom 6 were healthy and 12 were osteoporotic. When placed under the tongue the tablets, which were odourless and of pleasant taste, dissolved within one minute at the most.

Blood samples were taken at time 0 and at 5, 10, 20, 30, 60, 90 and 120 minutes after administration.

The calcitonin concentration in the serum was determined by radio-immunological assay.

55

The mean results for the 18 volunteers are shown in Figure 2.

These results show the appearance of salmon calcitonin in the blood within 4-5 minutes from administration. Side effects did not appear.

EXAMPLES 3-14

These examples describe formulations containing a calcitonin as active principle and usable for oral administration in the form of sublingual tablets.

5 The quantities indicated represent a formulation usable for preparing 1000 tablets each weighing about 100 mg.

	3)	ECT	50,000 U.I
10		Lactose	47.00 g
		Saccharose	40.00 g
15		Microcrystalline cellulose	10.00 g
		Amberlite IRP-88	0.50 g
		Sodium carboxymethyl starch	1.50 g
20		Magnesium stearate	1.00 g

25

30

35

40

45

50

55

	4)	ECT	50,000 U.I
		Lactose	47.00 g
5		Saccharose	40.00 g
		Microcrystalline cellulose	10.00 g
10		Amberlite IRP-88	2.00 g
		Magnesium stearate	1.00 g
	5)	ECT	50,000 U.I
15		Lactose	50.00 g
		Saccharose	32.00 g
		Microcrystalline cellulose	6.00 g
20		Explotab	2.00 g
		Magnesium stearate	0.90 g
	where Explotab is sodiumcarboxymethyl starch		
25	6)	SCT	50,000 U.I
		Lactose	42.00 g
30		Saccharose	40.00 g
		Microcrystalline cellulose	6.00 g
		Amberlite IRP-88	2.00 g
35		Magnesium stearate	0.90 g
	7)	(Asu ^{1.7})ECT	50,000 I.U.
		Lactose	42.00 g
40		Saccharose	40.00 g
		Microcrystalline cellulose	6.00 g
		Amberlite IRP-88	2.00 g
45	8)	SCT	50,000 U.I.
		Ludipress	50.00 g
		Saccharose	40.00 g
50		Microcrystalline cellulose	9.00 g

55

		Magnesium stearate	1.00 g
5	9)	(Asu ^{1.7})ECT	50,000 U.I.
		Ludipress	50.00 g
		Saccharose	40.00 g
10		Microcrystalline cellulose	9.00 g
		Magnesium stearate	1.00 g
	10)	ECT	100,000 I.U.
15		Lactose	42.00 g
		Saccharose	40.00 g
		Microcrystalline cellulose	6.00 g
20		Amberlite IRP-88	2.00 g
		Magnesium stearate	0.90 g
25	11)	ECT	150,000 I.U.
		Lactose	42.00 g
		Saccharose	40.00 g
30		Microcrystalline cellulose	6.00 g
		Amberlite IRP-88	2.00 g
		Magnesium stearate	0.90 g
35	12)	SCT	100,000 I.U.
		Lactose	42.00 g
40		Saccharose	40.00 g
		Microcrystalline cellulose	6.00 g
		Amberlite IRP-88	2.00 g
45		Magnesium stearate	0.90 g
	13)	SCT	150,000 I.U.
50		Lactose	42.00 g
		Saccharose	40.00 g

	Microcrystalline cellulose	6.00 g
	Amberlite IRP-88	2.00 g
5	Magnesium stearate	0.90 g
	14) (Asu ^{1.7})ECT	100,000 I.U.
	Lactose	42.00 g
10	Saccharose	40.00 g
	Microcrystalline cellulose	6.00 g
15	Amberlite IRP-88	2.00 g
	Magnesium stearate	0.90 g

20

EXAMPLE 15

Perbuccal tablets

25 Perbuccal tablets weighing about 150 mg were prepared having the following composition:

	ECT	50.00 I.U.
30	Lactose	69.75 mg
	Saccharose	69.75 mg
	Hydroxypropylmethylcellulose K100M	7.50 mg
35	Mg stearate	1.50 mg
	Talc	1.50 mg

40

These tablets were administered to a group of 10 volunteers, of whom 4 were healthy and 6 were osteoporotic. When placed between the upper gingiva and the cheek the tablets, which were odourless and of pleasant taste, dissolved within a time variable between 30 and 60 minutes without leaving residues and without impeding phonation.

45 Blood samples were taken at time 0 and at 15, 30, 60 and 120 minutes after administration.

The calcitonin concentration in the serum was determined by radio-immunological assay.

The mean results for the 10 volunteers are shown in Figure 3.

These results show the appearance of eel calcitonin in the blood within 10 minutes from administration.

The ECT concentration remained within acceptable values for 180 minutes.

50 Side effects did not appear.

EXAMPLES 16-28

These examples describe formulations containing a calcitonin as active principle and usable for oral
55 administration in the form of perbuccal tablets.

The quantities indicated represent a formulation usable for preparing 1000 tablets each weighing about 150 mg.

	16)	ECT	50,000 I.U.
		Lactose	66.00 g
5		Saccharose	66.00 g
		Hydroxypropylmethylcellulose	15.00 g
10		Mg stearate	1.50 g
		Talc	1.50 g
	17)	ECT	50,000 I.U.
15		Lactose	66.00 g
		Saccharose	66.00 g
20		Hydroxypropylmethylcellulose K100M	15.00 g
		Mg stearate	1.50 g
25		Talc	1.50 g
30			
35			
40			
45			
50			
55			

	18)	ECT	50,000 I.U.
		Lactose	68.50 g
5		Saccharose	68.50 g
		Gum arabic	10.00 g
10		Mg stearate	1.50 g
		Talc	1.50 g
	19)	ECT	50,000 I.U.
15		Lactose	69.75 g
		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	3.75 g
20		Hydroxypropylmethylcellulose K4Ms	3.75 g
		Mg stearate	1.50 g
		Talc	1.50 g
25	20)	ECT	50,000 I.U.
		Lactose	69.75 g
30		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	5.00 g
		Hydroxypropylmethylcellulose K4Ms	2.50 g
35		Mg stearate	1.50 g
		Talc	1.50 g
40	21)	ECT	100,000 I.U.
		Lactose	69.75 g
		Saccharose	69.75 g
45		Hydroxypropylmethylcellulose K100M	7.50 g
		Mg stearate	1.50 g
50		Talc	1.50 g

	22)	ECT	150,000 I.U.
5		Lactose	69.75 g
		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	7.50 g
10		Mg stearate	1.50 g
		Talc	1.50 g
	23)	SCT	50,000 I.U.
15		Lactose	69.75 g
		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	7.50 g
20		Mg stearate	1.50 g
		Talc	1.50 g
	24)	(Asu ^{1,7})ECT	50,000 I.U.
25		Lactose	69.75 g
		Saccharose	69.75 g
30		Hydroxypropylmethylcellulose K100M	7.50 g
		Mg stearate	1.50 g
		Talc	1.50 g
35	25)	SCT	100,000 I.U.
		Lactose	69.75 g
		Saccharose	69.75 g
40		Hydroxypropylmethylcellulose K100M	7.50 g
		Mg stearate	1.50 g
		Talc	1.50 g
45	26)	(Asu ^{1,7})ECT	100,000 I.U.
		Lactose	69.75 g
50		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	7.50 g

55

		Mg stearate	1.50 g
		Talc	1.50 g
5	27)	SCT	150,000 I.U.
		Lactose	69.75 g
10		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	7.50 g
		Mg stearate	1.50 g
15		Talc	1.50 g
	28)	(Asu ^{1.7})ECT	150,000 I.U.
20		Lactose	69.75 g
		Saccharose	69.75 g
		Hydroxypropylmethylcellulose K100M	7.50 g
25		Mg stearate	1.50 g
		Talc	1.50 g

30

Claims

1. Pharmaceutical compositions containing a calcitonin as active principle and suitable for preparing sublingual and peribuccal tablets for oral administration, characterised by containing a calcitonin homogenized with a mixture of solid excipients.
2. A pharmaceutical composition as claimed in claim 1 suitable for preparing sublingual tablets for the oral administration of a calcitonin, characterised in that the calcitonin is homogenized with a completely soluble diluent, a disintegrating agent and a lubricant.
3. A pharmaceutical composition as claimed in claim 2, wherein the diluent is mannitol or one or more sugars chosen from lactose and saccharose.
4. A pharmaceutical composition as claimed in claim 2, wherein the disintegrating agent is chosen from starch and its derivatives, microcrystalline cellulose and its derivatives, crospovidone, amberlite and alginic acid.
5. A pharmaceutical composition as claimed in claim 2, wherein the lubricant is chosen from the group consisting of magnesium stearate, aluminium stearate, stearic acid, talc and high molecular weight polyethyleneglycol.
6. A pharmaceutical composition as claimed in claim 1 suitable for preparing peribuccal tablets for the oral administration of a calcitonin, characterised in that the calcitonin is homogenized with a completely soluble diluent, a binder and a lubricant.
7. A pharmaceutical composition as claimed in claim 6, wherein the diluent is mannitol or one or more sugars chosen from lactose and saccharose.

8. A pharmaceutical composition as claimed in claim 6, wherein the binder is chosen from gum arabic, hydroxypropylcellulose and hydroxypropylmethylcellulose.
9. A pharmaceutical composition as claimed in claim 6, wherein the lubricant is chosen from the group consisting of magnesium stearate, aluminium stearate, stearic acid, talc and high molecular weight polyethyleneglycol.
10. A pharmaceutical composition as claimed in claim 1, wherein the active principle is eel calcitonin.
11. A pharmaceutical composition as claimed in claim 1, wherein the active principle is present in a quantity of between 20 and 800 U.I. per tablet.
12. A pharmaceutical composition as claimed in claim 11, wherein the active principle is present in a quantity of between 50 and 500 U.I. per tablet.
13. An oral administration dosage form in the form of a sublingual tablet prepared using the formulation in accordance with claims 2 to 5.
14. An oral administration dosage form in the form of a peribuccal tablet prepared using the formulation in accordance with claims 6 to 9.
15. A dosage form as claimed in claims 13 and 14, containing between 50 and 500 I.U. of a calcitonin as active principle.




FIG. 1




FIG. 2




FIG.3



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 438 147 A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **91100509.8**

(51) Int. Cl.⁵: **A61K 37/30, A61K 9/20**

(22) Date of filing: **17.01.91**

(30) Priority: **19.01.90 IT 1911290**

(43) Date of publication of application:
24.07.91 Bulletin 91/30

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(86) Date of deferred publication of the search report:
16.10.91 Bulletin 91/42

(71) Applicant: **SCLAVO S.p.A.**
Via Fiorentina 1
I-53100 Siena(IT)

(72) Inventor: **Lattanzi, Filippo**
Via Sansedoni, 9
I-53100 Siena(IT)
Inventor: **Cecchettin, Maurizio**
Via Diaz, 13/C
I-25100 Brescia(IT)
Inventor: **Vanni, Riccardo**
Via Montesanto, 3
I-53100 Siena(IT)

(74) Representative: **Gervasi, Gemma et al**
NOTARBARTOLO & GERVASI Srl Viale
Bianca Maria 33
I-20122 Milan(IT)

(54) **Pharmaceutical compositions and dosage forms for the oral administration of calcitonin.**

(57) New pharmaceutical compositions containing a calcitonin as active principle and suitable for oral administration in the form of peribuccal and sublingual tablets are described, in which the active principle is homogenized with a mixture of solid excipients, said excipients consisting of a diluent, a lubricant, a disintegrating agent in the case of sublingual tablets, and a binder in the case of peribuccal tablets.

Said compositions enable the same pattern of systemic levels to be obtained for the same unit dose as obtainable by conventional intramuscular administration.

EP 0 438 147 A3



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 10 0509

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	FR-A-2 623 090 (ISF S.p.A.) * Abstract; page 6, line 35 - page 7, line 10; page 7, lines 28-34; page 10, lines 2-12; page 10, line 32 - page 11, line 4; examples 51-56 * - - -	1-3,5-7, 9-15	A 61 K 37/30 A 61 K 9/20
X	DERWENT FILE SUPPLIER WPIL, 1987, AN = 87-053768 [08], Derwent Publications Ltd, London, GB; & JP-A-62 010 020 (KANEBO K.K.) * Abstract * - - -	1,2,4,6,8, 10	
X	DERWENT FILE SUPPLIER WPIL, 1987, AN = 87-280978 [40], Derwent Publications Ltd, London, GB; & JP-A-62 195 336 (SEKISUI CHEM. IND) * Abstract * - - -	1,2,10	
A	CHEMICAL ABSTRACTS, vol. 96, no. 12, March 1982, page 408, abstract no. 91645k, Columbus, Ohio, US; & JP-A-81 140 924 (TEIJIN LTD) 04-11-1981 * Abstract * - - - - -	1-15	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
The Hague		25 July 91	HOFF P.J.L.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document			